Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Francesco, Pierantoni"'
Autor:
Michele Dionese, Umberto Basso, Francesco Pierantoni, Eleonora Lai, Nicolò Cavasin, Elisa Erbetta, Salim Jubran, Giorgio Bonomi, Davide Bimbatti, Marco Maruzzo
Publikováno v:
Future Science OA, Vol 9, Iss 7 (2023)
Aim: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). Materials & methods: in 72 patients treated with ICIs for metastatic urot
Externí odkaz:
https://doaj.org/article/e7a92d8288ff47c9829ad4d408f11ea4
Autor:
Davide Bimbatti, Michele Dionese, Eleonora Lai, Nicolò Cavasin, Umberto Basso, Alvise Mattana, Francesco Pierantoni, Vittorina Zagonel, Marco Maruzzo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionImmunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosi
Externí odkaz:
https://doaj.org/article/e7c9bff5d3e444d686cbd29b7d26c867
Autor:
Michele Dionese, Umberto Basso, Gaetano Ramondo, Francesco Pierantoni, Davide Bimbatti, Francesca Caumo, Vittorina Zagonel, Marco Maruzzo
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
The role of percutaneous tumour biopsies had gain importance in the management of renal cell carcinoma to provide diagnostic specimen for the patients with metastatic disease that could benefit a systemic treatment. Among the possible complications o
Externí odkaz:
https://doaj.org/article/6a614cddd52a4915883069c625b94cdb
Autor:
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Marco Maruzzo, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Mariella Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This m
Externí odkaz:
https://doaj.org/article/b7fbd6a0e95e4fbc8e3f9aaff8b8f0d2
Autor:
Evgeniya Sharova, Marco Maruzzo, Paola Del Bianco, Ilaria Cavallari, Francesco Pierantoni, Umberto Basso, Vincenzo Ciminale, Vittorina Zagonel
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Androgen Receptor-Targeted Agents (ARTA) have dramatically changed the therapeutic landscape of metastatic Castration-Resistant Prostate Cancer (mCRPC), but 20–40% of these patients progress early after start of ARTA treatment. The present study in
Externí odkaz:
https://doaj.org/article/33ac3c48ac3747d2ad21582db935700a
Autor:
Francesco Pierantoni, Marco Maruzzo, Antonella Brunello, Benedetta Chiusole, Grazia Pusole, Elisabetta Bezzon, Umberto Basso, Vittorina Zagonel
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Soft tissue sarcomas are rare neoplasms, with a high mortality rate. Few drugs are available for the treatment of patients affected by metastatic sarcomas, who still have a 5-years survival rate lower than 20%. However, some of the more recent therap
Externí odkaz:
https://doaj.org/article/292dd25861ec44f0800b0d0e24bba5d6
Autor:
Francesco Pierantoni, Michele Dionese, Umberto Basso, Eleonora Lai, Nicolò Cavasin, Elisa Erbetta, Alvise Mattana, Davide Bimbatti, Vittorina Zagonel, Sara Lonardi, Marco Maruzzo
Publikováno v:
Clinical Genitourinary Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a620313acac5ef13a10184f45f379d66
https://doi.org/10.1016/j.clgc.2023.04.006
https://doi.org/10.1016/j.clgc.2023.04.006
Autor:
Francesca Vignani, Rosa Tambaro, Ugo De Giorgi, Patrizia Giannatempo, Davide Bimbatti, Claudia Carella, Marco Stellato, Francesco Atzori, Michele Aieta, Cristina Masini, Alketa Hamzaj, Paola Ermacora, Antonello Veccia, Giuseppa Scandurra, Teresa Gamba, Gianluca Ignazzi, Sandro Pignata, Marilena Di Napoli, Cristian Lolli, Giuseppe Procopio, Francesco Pierantoni, Antonia Zonno, Daniele Santini, Massimo Di Maio
Platinum-based chemotherapy (PBCT) is the standard first-line treatment for advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized between platinum drugs and poly-ADP ribose-polymerase (PARP) inhibitors.To compare mainten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84477958d8d2a561ad2f8807b97a8a96
https://hdl.handle.net/2318/1887415
https://hdl.handle.net/2318/1887415
Autor:
Davide Bimbatti, Giuseppina Tierno, E. Bergo, E. Lamberti, Marco Maruzzo, Umberto Basso, Antonella Brunello, Vittorina Zagonel, Francesco Pierantoni
Publikováno v:
Journal of Geriatric Oncology. 12:290-297
There is poor data on the prognostic role of Comprehensive Geriatric Assessment (CGA) in older patients with metastatic renal cell carcinoma (mRCC) treated with first line Tyrosine Kinase Inhibitors (TKIs).We retrospectively reviewed the clinical cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c91e17fde65fca65ff488d5ca7890df
https://doi.org/10.1016/j.jgo.2020.09.009
https://doi.org/10.1016/j.jgo.2020.09.009
Autor:
Davide, Bimbatti, Eleonora, Lai, Francesco, Pierantoni, Marco, Maruzzo, Aichi, Msaki, Chiara, De Toni, Michele, Dionese, Alessandra, Feltrin, Umberto, Basso, Vittorina, Zagonel
Publikováno v:
Patient preference and adherence. 16
Testicular cancer (TC) is the most common solid tumor in young adults. 95% of patients are cured, but they may experience late adverse effects (anxiety, fear of recurrence, and sexual dysfunction) with an impact on daily life. We attempted to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ecf9686cedd96637cf99ce399f675025
https://pubmed.ncbi.nlm.nih.gov/36582267
https://pubmed.ncbi.nlm.nih.gov/36582267